Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children
Nobili V, Alisi A, Della Corte C, Risé P, Galli C, Agostoni C, Bedogni G
Nutrition, metabolism, and cardiovascular diseases : NMCD · 111 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2012-12-07 · Nutr Metab Cardiovasc Dis · vol. 23 · número 11 · págs. 1066–1070
- Editorial
- Elsevier BV
- Citado
- 143 citas · más que el 97% de estudios similares · 6.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 31 trabajos
- Acceso
- De pago
- Áreas de investigación
- Liver Disease Diagnosis and Treatment · Fatty Acid Research and Health · Aquaculture Nutrition and Growth
- Palabras clave
- docosahexaenoic acid, non-alcoholic fatty liver disease, pediatric NAFLD, omega-3 supplementation, hepatic steatosis, liver fat, triglycerides, alanine aminotransferase, insulin resistance, dose comparison
- MeSH
- liver, humans, fatty liver, hepatic insufficiency, insulin resistance, hypertriglyceridemia, docosahexaenoic acids, triglycerides, ultrasonography, body mass index, severity of illness index, follow-up studies, down-regulation, dietary supplements, adolescent, child, hospitals, pediatric, italy, female, male, lipid metabolism, non-alcoholic fatty liver disease
7 autores
- Valério Nobili🇮🇹 · autor de correspondenciaBambino Gesù Children's Hospital
- Anna Alisi🇮🇹Bambino Gesù Children's Hospital
- Claudia Della Corte🇮🇹Bambino Gesù Children's Hospital
- Patrizia Risé🇮🇹University of Milan
- Claudio Galli🇮🇹University of Milan
- Carlo Virginio Agostoni🇮🇹University of Milan; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
- Giorgio Bedogni🇮🇹University of Milan; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Bambino Gesù Children's Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background and aim
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in children. We tested whether dietary supplementation with docosahexaenoic acid (DHA) can decrease liver fat content in children with NAFLD.
Methods and results
We performed a randomized controlled trial of DHA supplementation (250 mg/day and 500 mg/day) vs. placebo in 60 children with NAFLD (20 children per group). The main outcome was the change in liver fat as detected by ultrasonography after 6, 12, 18 and 24 months of treatment. Secondary outcomes were changes in triglycerides, alanine transaminase (ALT), body mass index (BMI) and homeostasis model assessment of insulin resistance (HOMA). The odds of more severe versus less severe liver steatosis decreased to the same degree at 6 months in children treated with DHA 250 mg/day and DHA 500 mg/day vs. placebo and persisted virtually unmodified for 24 months (OR ≤ 0.02, p ≤ 0.05 for all time points). Triglycerides were lower in the DHA groups than in the placebo group at any time point and ALT was lower in these groups from month 12 onwards. HOMA was lower in the DHA 250 mg group vs. placebo at months 6 and 12.
Conclusion
DHA supplementation improves liver steatosis in children with NAFLD. Doses of 250 mg/day and 500 mg/day of DHA appear to be equally effective in reducing liver fat content.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.